About the company
Founded in 2008, BioNTech SE has grown to become a leading biotechnology company at the forefront of medical innovation. With a strong focus on cancer therapeutics and infectious disease vaccines, BioNTech is dedicated to improving the lives of patients around the world. BioNTech's impressive oncology pipeline encompasses a wide range of innovative drug classes. Their mRNA-based drugs are designed to encode antigens, neoantigens, cytokines, and antibodies. By utilizing the body's own cellular machinery, these mRNA-based drugs hold immense potential for individualized immunotherapy. This approach has the ability to stimulate the immune system to target and destroy cancer cells specifically, while sparing healthy cells. In addition to mRNA-based drugs, BioNTech is also developing cell therapies that harness the power of immune cells to fight cancer. By engineering immune cells, such as T cells, to recognize and attack cancer cells, these therapies offer a unique and highly targeted approach to cancer treatment. The company's pipeline also includes bispecific antibodies, which are designed to bind to both cancer cells and immune cells, enhancing the immune response against tumors. By simultaneously targeting multiple antigens, bispecific antibodies have the potential to further heighten the efficacy of cancer immunotherapy. Furthermore, BioNTech is exploring the use of small-molecule immunomodulators. These molecules are capable of modulating the immune system to facilitate a stronger response against cancer cells. By altering the immune microenvironment, these immunomodulators have the potential to improve the effectiveness of other therapeutic approaches. BioNTech's collaborations with major pharmaceutical companies, such as Roche, Eli Lilly, Pfizer, Sanofi, and Genmab, further strengthen their position in the field of biotechnology. These partnerships provide resources and expertise to accelerate the development and commercialization of their innovative therapies. One of BioNTech's most notable achievements is the successful development and commercialization of Comirnaty, a COVID-19 vaccine. In collaboration with Pfizer, BioNTech leveraged their mRNA technology to rapidly develop a highly effective vaccine against the SARS-CoV-2 virus. Comirnaty has played a crucial role in global efforts to combat the COVID-19 pandemic, providing hope and protection to millions of people worldwide. With their diverse pipeline and strong partnerships, BioNTech continues to push the boundaries of medical science. Their commitment to developing groundbreaking therapies for cancer and infectious diseases has the potential to revolutionize the field of biotechnology and improve the lives of countless patients. As BioNTech continues to innovate and collaborate, the future holds immense promise for the company and the patients they aim to serve.
Website: https://www.biontech.de
Data updated: May 4, 2026
